ERBB2 and breast cancer: The HER2+ subtype of breast cancer, known for its poorer prognosis compared to luminal breast cancer [30,31], saw a significant treatment advancement in 1998 with the approval of trastuzumab for this subpopulation of metastatic breast cancer [5,32].